Skip to content

Transforming your biomedical data into actionable insights

We are your agile data science partner with expertise in biomedical data analysis, data mining, data integration, pipeline development, machine learning and artificial intelligence, software engineering and more.


Who we work with

We support biotech, pharmaceutical and diagnostic companies, and research institutions of all sizes to enable truly data-driven discovery, preclinical, translational and clinical R&D processes. We also have robust experience working in the animal health field as well as in supporting food and agriculture R&D.

What we do

Leveraging our expertise in advanced bioinformatics, predictive analytics & AI, tailored software development, and data governance & architecture to support you in data-driven research and development and (pre)clinical studies.

Learn more →

BioLizard provided a highly professional and skilled deliverable to our request. The outcome and analysis of the hypothesis will help us in the decision-making process to identify an efficient strategy for further development of the drug product.

- Sillar Clinical

idea2 Tailored solutions

We help you make better, more data-driven decisions faster. Our goal? Supporting you in getting the most out of your biomedical data.


Bio|Verse platform               

We strongly believe that creating data-driven biological insights requires a combination of computational power, human input and collaboration. 

datadriven Data-driven services

We are your agile data science partner with expertise in biomedical data analysis, data mining, pipeline development, AI and more.


Knowledge hub                  

We’re dedicated to fostering deep and broad expertise in our team of Lizards - and we’ve collected all our knowledge here for you to explore.

How we do it

BioLizard brings together a diverse yet complementary range of expertises to implement the most up-to-date technological tools to meet your unique data needs, now and in the future. We believe that an inclusive and open communication strategy with our clients is essential for the successful completion of each project. We ensure to align regularly with you throughout the process, and adjust pipelines to best fit your unique data case and maximize your output.

When you partner with BioLizard, you get state-of-the-art data analysis pipelines and tools to apply to your current and future research projects - and moreover, you receive end-to-end support that will make it faster and easier for you to turn your data into actionable insights. We also always ensure to fully explain our data science approach to solving your biological challenges - there’s no black box when you work with BioLizard.



A personalized, agile service model for truly impactful results

BioLizard featured in Scrip Asks

BioLizard has been featured in 𝗦𝗰𝗿𝗶𝗽 𝗔𝘀𝗸𝘀...𝗪𝗵𝗮𝘁 𝗗𝗼𝗲𝘀 𝟮𝟬𝟮𝟰 𝗛𝗼𝗹𝗱 𝗙𝗼𝗿 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮? 𝗣𝗮𝗿𝘁 𝟰: 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆.

Our CEO, Liesbeth Ceelen, shared her insights about what we can expect in the coming year where AI and data analytics meet the life sciences.

Liesbeth predicts: “In the coming year, we expect to see the pharma sector build up its data infrastructure to enable high-quality data analytics, while implementation and utilisation of AI will ultimately remain the task of the small number of experts with both biological and data analytics expertise.” 

Learn more →

Liesbeth quote - Scrip

BioLizard joins BioWin

We are happy to announce that BioLizard has joined BioWin, the health cluster in Wallonia, Belgium.

BioWin is the regional reference for all stakeholders in health, biotech and medtech research, and innovation projects. It currently encompasses 250 members from the private, public and academic sectors.

Read more →

BioLizard joins biowin

Appointment of André van de Sande as Chairman of the Board

We are pleased to announce the appointment of André van de Sande as the new Chair of our Board of Directors. 

As a Senior Executive with 30 years of life sciences experience and a track record in both mature and emerging markets across the regions of Western and Central Europe, Asia Pacific, Middle East and Africa, André van de Sande brings highly valuable, proven expertise to BioLizard.

Having already served as a Strategic Advisor to BioLizard starting in 2020, and thereafter as Board Member & Independent Director since spring 2023, we are thrilled to now welcome him as Chairman of the Board.

Read more →


BioLizard nominated for a VLAIO Award

We are thrilled to announce that we have been nominated for the first VLAIO Awards.

VLAIO stimulates and supports innovative entrepreneurship in Flanders, and with the VLAIO Awards they are putting companies that have made a meaningful impact with their projects in the spotlight.

We are one of three companies selected by the jury within the category, 𝙚𝙘𝙤𝙣𝙤𝙢𝙞𝙘 𝙞𝙢𝙥𝙖𝙘𝙩. The ultimate winner be awarded on March 19, 2024 during the FTI AND& city festival in Leuven.

Read more →

VLAIO award

BioLizard announces Swiss subsidiary

We are proud to announce that we have made an exciting new step in our continued international expansion, while deepening our commitment to our current and future Swiss partners and clients.

With the opening of our newest office at Biopôle Lausanne, we have officially entered the Swiss market. Biopôle, which houses 120 companies, provides the perfect conditions for us to engage with the Swiss biotech industry and offer our services exactly where our clients need them.

Read more →

Swiss subsidiary

BioLizard featured in GoingPublic

BioLizard's role in head­ing digital transformation in the life ­sciences industry has been featured in the trade magazine GoingPublic.

This article highlights BioLizard as a driver for sustainability in the industry, as our technology helps to transfer research from in vitro to in silico settings, which can save natural resources and minimise waste.

Read more →

Screenshot 2024-01-03 at 09.43.44

BioLizard's AI expertise highlighted in European Biotechnology

"Depending on who you talk to, artificial intelligence (AI) is either a saviour or an enslaver. The concerns range from loss of jobs through to robots running society. However, in the life sciences, the use of AI and machine learning (ML) have created some excitement over their potential applications."

Our CEO Liesbeth Ceelen shares her expertise in an article published in European Biotechnology.

Learn more →

AI tool or trouble

Trusted by

cytura therapeutics logo-2
U Ghent Vetrinary Sciences-2
Rarety logo färg